Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, discusses how practices and administrators can build higher pathway compliance

Published: 13 February 2017

Recent Videos

video

Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML

Dr. Pratz discusses the epidemiology and cytogenetic risk associated with acute myeloid leukemia (AML)

video

Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML

Dr. Pratz considers whether we can combine ivosidenib or enasidenib with standard induction chemotherapy in newly diagnosed acute myeloid leukemia ...

video

Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients

Dr. Pratz shares the outcomes of the venetoclax with decitabine or azacitidine study in treatment-naive acute myeloid leukemia (AML) patients

video

Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients

Dr. Pratz evaluates some of the exciting clinical data with FLT3 tyrosine kinase inhibitors in acute myeloid leukemia (AML) patients ...

video

Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients

Dr. Pratz offers his opinion on strategies for treating frail acute myeloid leukemia (AML) patients who do not quality for ...

video

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

Dr. Lane elaborates on the efficacy outcomes of SL-401 consolidation therapy in patients with acute myeloid leukemia (AML)

video

Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients

Dr. Pratz tells us how he is incorporating Vyxeos (liposomal daunorubicin and cytarabine) into his practice for acute myeloid leukemia ...

video

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

Dr. Lane discusses how minimal residual disease is being integrated into treatment decision making in acute myeloid leukemia (AML) patients

video

Keith Pratz, MD, on the proportion of AML patients who fall into the frail category

Dr. Pratz describes the proportion of acute myeloid leukemia (AML) patients who fall into the category of frail

video

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

Dr. Hagemeister shares what physicians should know about the development of CAR T-cell therapies in lymphoid malignancies

Related Videos

video-image

Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML

video-image

Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML

video-image

Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients

video-image

Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients

video-image

Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients

video-image

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

video-image

Keith Pratz, MD, on the proportion of AML patients who fall into the frail category

video-image

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

video-image

Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies

video-image

Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment

video-image

Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types

video-image

Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma

video-image

Parameswaran Hari, MD, MRCP, MS, provides an update on how MM patients are staged at diagnosis

video-image

Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients

video-image

Parameswaran Hari, MD, MRCP, MS, discusses the clinical relevance of minimal residual disease

video-image

Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MM

video-image

Parameswaran Hari, MD, MRCP, MS, considers the remaining unmet medical needs in MM

video-image

John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma